plasma-derived products are used in Australia in a wide variety of clinical settings. The majority of these products are manufactured locally from voluntary blood donations. The preparation of plasma products is subject to rigorous safety measures, including screening blood donors, testing plasma for infectious material, and subjecting plasma to dedicated pathogen inactivation steps. The safe use of plasma derivatives requires correct storage and handling.
Introduction
Plasma derivatives, prepared by fractionating donated human plasma, are used in a wide range of medical conditions. Australia's national policy for these essential products is to strive for self-sufficiency. A recent review of the policy found that, while Australia has never completely produced all of its own plasma derivatives, 'Australia should be as self-sufficient as possible, and that self-sufficiency should remain an important goal'. 1 
plasma products used in Australia
Plasma-derived products can be divided into three broad categories: immunoglobulins, coagulation factors and albumin (Table 1) . These are primarily used to replace missing or dysfunctional elements of the immune or coagulation systems. In the case of RhD immunoglobulin or intravenous immunoglobulin, their primary role is to modulate the immune system's responses. The uses of intravenous immunoglobulin continue to increase, 2 particularly as immunological bases for more conditions are revealed. Future demand for intravenous immunoglobulin may be altered by the advent of new, more targeted therapies for conditions with an autoimmune basis. The demand for coagulation factors is influenced by the availability of specific recombinant products which are not plasma-derived.
plasma supply
The Australian Red Cross Blood Service, under medical oversight and operating within the principles of Good Manufacturing Practice and a licence from the Therapeutic Goods Administration (TGA), collects plasma from volunteer, non-remunerated donors.
The safety of these blood-derived products remains of utmost importance. Although Australia's blood supply is safer than it has ever been from an infectious diseases point of view, vigilance is still required against known pathogens (such as prions associated with variant Creutzfeldt-Jakob disease), currently unknown pathogens and other associated risks.
The Blood Service actively monitors for new and emerging infectious threats to blood safety.
Screening blood donors
Stringent criteria must be met before the donation of blood is permitted in Australia, and recruitment and retention of low-risk, volunteer donors is a key element in maintaining the safety of the plasma supply. Donors with temporary or indefinite ineligibility are deferred as appropriate, to minimise the risks of pathogens being present in the plasma sent for fractionation. Each donor undergoes a detailed, confidential interview and health screen.
Collecting, testing and processing plasma
once donor eligibility has been established, collection of whole blood or plasma (by plasmapheresis) occurs in accordance with strict safety and quality requirements. Whole blood is separated into its components (red cells, platelets and plasma) within specified time and temperature conditions to maintain plasma integrity. Bar coding of all samples and kits permits traceability at each step of the process.
All donor samples undergo pathogen screening using routine serological and nucleic acid testing (see box). Targeted serological testing may also be performed, such as malaria testing for a donor with a relevant travel history. Albumin and saline for volume replacement in the critically ill were found to be equally safe and effective. 9 Albumin 20% Used in shock and hypoproteinaemic states such as burns and paracentesis of ascites 
Manufacturing plasma products
The majority of plasma-derived products used in Australia 
Plasma fractionation
The fractionation process includes physical separation using 
Quality control
The fractionation process proceeds under strict regulatory oversight in a highly controlled manufacturing environment.
Cleaning and sanitation protocols prevent cross-contamination of batches. Quality control and release testing monitors interim and final products against approved plasma specifications agreed upon by the manufacturer and the TGA. 
Using fractionated plasma products
Blood products should only be prescribed with awareness of their associated harms and benefits. All plasma products used 
Storage and handling
Storage and transport requirements are defined for all plasmaderived products. They require storage in secure, monitored environments to ensure their safety and efficacy. Some require refrigeration, while others may be stored at controlled room temperature routinely or for short periods.
Although safety-related recalls are rare, the ability to trace each product to its final destination (transfusion to a patient) is a requirement documented in health department circulars and other regulations in a number of states. 7
Adverse reactions
Adherence to the manufacturer's guidance and institutional infusion policies, and careful monitoring of the patient during infusion, can minimise the likelihood of adverse events, or allow for early intervention should they occur.
Serious adverse reactions to plasma products are rare, but minor reactions are not uncommon. When serious reactions do occur, they should be reported promptly to the local transfusion service (hospital blood bank or issuing laboratory), and the manufacturer.
Medical advice regarding reporting and management of adverse reactions is available through the manufacturer or distributor and the Australian Red Cross Blood Service.
recombinant products
Currently, recombinant products are used primarily for coagulation factor therapy in patients with bleeding disorders and include factor VIIa, factor VIII (haemophilia A) and factor IX 
Conclusion
The process from blood donation to administration of a fractionated blood product is lengthy and complex, with multiple checkpoints to deliver safe and effective products.
As treating clinicians, it is our responsibility to ensure that they are administered correctly and for the appropriate indications. 
